StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultJul 31, 2026, 08:08 AM

Myriad Genetics Q2 Net Loss Narrows to $43.2M; Revenue Declines

AI Summary

Myriad Genetics reported a net loss of $43.2 million for Q2 2026, a significant narrowing from $330.5 million in Q2 2025, which included a substantial goodwill and long-lived asset impairment charge. Revenue for the quarter decreased to $190.7 million from $213.1 million year-over-year. The company also recognized a $4.5 million goodwill impairment charge in Q1 2026 related to its Women's Health reporting unit.

Key Highlights

  • Q2 2026 net loss was $43.2M, significantly narrowing from $330.5M in Q2 2025.
  • Q2 2026 revenue decreased to $190.7M from $213.1M in Q2 2025.
  • Basic and diluted net loss per share improved to $(0.46) from $(3.57) in Q2 2025.
  • Goodwill impairment charge of $4.5M recognized in Q1 2026 for Women's Health.
  • Net cash used in operating activities for H1 2026 was $(24.0)M, an improvement from $(29.9)M.
  • Stockholders approved the 2026 Employee, Director and Consultant Equity Incentive Plan.
  • Cancer Care Continuum revenue was $114.1M in Q2 2026, down from $127.7M.
  • Prenatal Health revenue was $39.8M in Q2 2026, down from $47.6M.